OliX Pharmaceuticals to Conduct One-on-One Meetings with Potential Partners at BIO Digital 2021 Conference
10 juin 2021 15h00 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, June 10, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
OliX Pharmaceuticals Signs Agreement with LGC Biosearch Technologies to Accelerate Production of Asymmetric siRNA for the Treatment of Androgenic Alopecia
09 juin 2021 10h00 HE
|
OliX Pharmaceuticals
SEOUL, Republic of Korea and LONDON, June 09, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, and LGC, a global leader in the life...
OliX Pharmaceuticals Subsidiary mCureX Announces Business Agreements to Advance Development of mRNA Vaccines and Therapeutics
07 juin 2021 08h00 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, June 07, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company’s subsidiary mCureX has...
OliX Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for Improved Intracellular Delivery Platform Technology for RNAi Therapeutics
24 mai 2021 08h00 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, May 24, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced that the Company has received a notice of...
OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate
10 févr. 2021 17h45 HE
|
OliX Pharmaceuticals
Company to discuss study results and present corporate overview at SMi’s 12th Annual RNA Therapeutics Virtual Conference on February 11 SUWON, Republic of Korea, Feb. 10, 2021 (GLOBE NEWSWIRE) --...
OliX Pharmaceuticals Launches New Subsidiary to Develop mRNA Vaccines and Therapeutics
08 févr. 2021 07h00 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Feb. 08, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, has announced the establishment of mCureX...
OliX Pharmaceuticals to Present at 2021 ICR Conference
06 janv. 2021 07h00 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Jan. 06, 2021 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will...
OliX Announces Completion of $37.2 Million Capital Raise to Support U.S. Expansion and Advance Pipeline Globally
01 déc. 2020 07h00 HE
|
OliX Pharmaceuticals
Capital to fund construction of RNA synthesis GMP facility in San DiegoSupports company’s goal of having 10 programs entered into clinical trials by 2024 SUWON, Republic of Korea, Dec. 01, 2020 ...
OliX Pharmaceuticals Announces FDA Clearance of the IND to Evaluate the Efficacy of OLX10010 in Phase 2a Clinical Trial for Hypertrophic Scars
30 oct. 2020 10h02 HE
|
OliX Pharmaceuticals
Potential first-in-class treatment for hypertrophic scars with no FDA-approved medicines to-datePhase 2a trial follows the successful completion of OliX’s Phase 1 trial in the U.K. in November...
OliX Pharmaceuticals to Present at OPT Congress and BIO-Europe
20 oct. 2020 13h31 HE
|
OliX Pharmaceuticals
SUWON, Republic of Korea, Oct. 20, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that Dong Ki Lee, Ph.D., founder...